Rosen Law Firm Urges OCGN Investors to Act Ahead of June Deadline

Investors holding shares of Ocugen, Inc. OCGN, a biopharmaceutical company specializing in gene therapies for ocular diseases, have been alerted by Rosen Law Firm to take action prior to a critical deadline. The firm, known for advocating for investor rights globally, has set a June 10 deadline for shareholders to seek counsel in connection with a securities class action initially launched by the firm.

Reminder for OCGN Shareholders

Rosen Law Firm is reminding investors of their legal rights amidst allegations of potential securities fraud. The firm emphasizes the importance of the upcoming June 10 deadline to plaintiffs who have incurred losses in OCGN securities due to possible misleading information from the company.

Understanding Ocugen's Position

OCGN is headquartered in Malvern, Pennsylvania, and focuses primarily on developing treatments for blindness-related diseases through gene therapy. OCGN has acquired attention not just for its innovative clinical approaches but also due to fluctuations in its stock performance, making it a notable entity in the investment community.

Investment, Legal, Deadline